10 Best Long Term Healthcare Stocks to Buy

5. Ardelyx, Inc. (NASDAQ:ARDX)

Number of Hedge Fund Holders: 30

5-year Revenue Growth: 129.14%

Ardelyx, Inc. (NASDAQ:ARDX) reported preliminary, unaudited product revenue results for the fourth quarter and full year 2025, along with expected product revenue for 2026 and an updated long-term outlook for Ibsrela. The company delivered strong commercial performance in 2025, with Ibsrela revenue increasing 73% year over year, while maintaining patient access to Xphozah. Ardelyx also advanced its development pipeline by initiating a Phase 3 program for Ibsrela in chronic idiopathic constipation and beginning work on a next-generation NHE3 inhibitor, RDX10531. Entering 2026, the company indicated it is positioned for continued growth, supported by expanding commercial opportunities, ongoing pipeline development, and a solid cash position. Ardelyx emphasized its focus on advancing first-in-class therapies addressing unmet medical needs while investing in commercialization and development efforts to support long-term value creation.

Recent developments include the initiation of a Phase 3 trial evaluating Ibsrela in chronic idiopathic constipation, a larger and underpenetrated indication that could expand the drug’s addressable market. Ardelyx, Inc. (NASDAQ:ARDX) continues to report strong year-over-year revenue growth for Ibsrela, alongside increasing Xphozah sales. Updated guidance reflects expectations for Ibsrela to exceed $1 billion in peak sales, supported by patent protection extending to 2041. Advancement of the next-generation NHE3 inhibitor RDX10531 adds an additional pipeline asset alongside ongoing commercialization efforts.

Ardelyx, Inc. (NASDAQ:ARDX) was founded in October 2007 and is headquartered in Waltham, Massachusetts. The company develops therapies targeting gastrointestinal, cardio-renal, and metabolic diseases.